Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy

Raisa Perzova, Elliot Graziano, Swathi Sanghi, Caitlin Welch, Patricia Benz, Lynn Abbott, Danielle Lalone, Jordan Glaser, Thomas Loughran, William Sheremata, Bernard J. Poiesz

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Background: Previously, we had shown that persons infected with human T-cell lymphoma leukemia virus 1 or 2 (HTLV-1 or 2) had an increased prevalence of antibodies to a peptide in the Pol protein of the retrovirus HERV-K10, homologous to a peptide in HTLV gp21 envelope protein. The prevalence rate was higher in those with myelopathy vs. non-myelopathy. We have now extended our observations to a cohort restricted to North America in whom the diagnosis of HTLV myelopathy was rigorously confirmed to also test for reactivity to another HERV-K10 peptide homologous to the HTLV p24 Gag protein. Methods. Sera from 100 volunteer blood donors (VBD), 53 patients with large granular lymphocytic leukemia (LGLL), 74 subjects with HTLV-1 or 2 infection (58 non-myelopathy and 16 myelopathy) and 83 patients with multiple sclerosis (MS) were evaluated in ELISA assays using the above peptides. Results: The HTLV myelopathy patients had a statistically significant increased prevalence of antibodies to both HERV-K10 peptides (87.5%) vs. the VBD (0%), LGLL patients (0%), MS patients (4.8%), and the HTLV positive non-myelopathy subjects (5.2%). Conclusion: The data suggest that immuno-cross-reactivity to HERV-K10 peptides and/or transactivation of HERV-K10 expression by the HTLV Tax protein may be involved in the pathogenesis of HTLV-associated myelopathy/tropical spastic paraparesis and spastic ataxia.

Original languageEnglish
Article number360
JournalVirology Journal
Volume10
DOIs
StatePublished - Dec 23 2013

    Fingerprint

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Perzova, R., Graziano, E., Sanghi, S., Welch, C., Benz, P., Abbott, L., Lalone, D., Glaser, J., Loughran, T., Sheremata, W., & Poiesz, B. J. (2013). Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy. Virology Journal, 10, [360]. https://doi.org/10.1186/1743-422X-10-360